Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in ItalyE. Ferrazzi, Giuseppe Colucci, Francesco Di Costanzo et al.|Tumori Journal|2005Cited by 6
Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities?Francesca Daniel, Antonio Frassoldati, Lorenzo Belluomini et al.|Annals of Oncology|2016Cited by 1
The regorafenib issue: focus on efficacy and safety in pre-treated metastatic colorectal cancer from a real world experienceFrancesca Daniel, Antonio Frassoldati, E. Bannò et al.|Annals of Oncology|2017Cited by 1